Bryan Garnier - CELYAD: While CYAD-101 faces setback, shRNA platform is evolving with novel armoured approach | BUY | EUR12 VS. EUR14 (+231%)

Report

Bryan Garnier

Olga Smolentseva

CELYAD: While CYAD-101 faces setback, shRNA platform is evolving with novel armoured approach | BUY | EUR12 VS. EUR14 (+231%)

CELYAD - BUY | EUR12 VS. EUR14 (+231%)
While CYAD-101 faces setback, shRNA platform is evolving with novel armoured approach

shRNA platform gets armoured
Some setbacks with CYAD-101, but KEYNOTE-B79 is on track for Q421
Expecting decision on CYAD-02 by the year-end
Financial and model update

06/08/2021 5 EN

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports from Bryan Garnier

Cedric Rossi ... (+3)

Cedric Rossi
Clement Genelot
Loic Morvan

On the shelves now: Consumer Weekly #67

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the largest beauty groups in the world. Happy reading!

14h / 5m 14h / 5m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Kempower: Updating our model following Q1 results

Last Friday, Kempower published Q1 2025 results, reporting revenues of EUR43.5m (+2% YoY vs. EUR42.6m in Q1 2024), though revenues declined sequentially due to continued soft demand due to elevated inventory levels across the DC charging industry. Gross margin remained stable at 49.5% (-0.3ppt YoY)

17h / 5m 17h / 5m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Valneva: France suspends Ixchiq for >65yo pending investigation

Valneva's Ixchiq has been suspended by France's HAS (national public health agency) for the use in persons aged >65 y.o pending further investigation, after three cases of SAEs (all in patients >80, with one death) have been reported in the French pharmacovigilence database — these cases have

17h / 23m 17h / 23m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CELYAD: While CYAD-101 faces setback, shRNA platform is evolving with novel armoured approach | BUY | EUR12 VS. EUR14 (+231%)

On the shelves now: Consumer Weekly #67

Kempower: Updating our model following Q1 results

Valneva: France suspends Ixchiq for >65yo pending investigation

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe